Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Clinical trial NCT01788046 · COMPLETED

Trial details

NCT number: NCT01788046
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hyperparathyroidism, Secondary

Start date: 2013-03-12
Primary completion: 2014-04-14
Enrollment: 515

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.